323 related articles for article (PubMed ID: 9781280)
1. Whole-body [18F]FDG PET in the management of metastatic brain tumours.
Kim DG; Kim CY; Paek SH; Lee DS; Chung JK; Jung HW; Cho BK
Acta Neurochir (Wien); 1998; 140(7):665-73; discussion 673-4. PubMed ID: 9781280
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of dissemination studies with FDG whole-body positron emission tomography in patients with suspected metastatic tumours of brain and spine.
Go KG; Pruim J; Que TH; Vaalburg W; Haaxma-Reiche H
Acta Neurochir (Wien); 2000; 142(6):627-31. PubMed ID: 10949436
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors.
Gupta NC; Nicholson P; Bloomfield SM
Ann Surg; 1999 Aug; 230(2):202-6. PubMed ID: 10450734
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors.
Jeong HJ; Chung JK; Kim YK; Kim CY; Kim DG; Jeong JM; Lee DS; Jung HW; Lee MC
J Nucl Med; 2002 Nov; 43(11):1432-7. PubMed ID: 12411544
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
[TBL] [Abstract][Full Text] [Related]
8. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors.
Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z
Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148
[TBL] [Abstract][Full Text] [Related]
9. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.
Dietlein M; Krug B; Groth W; Smolarz K; Scheidhauer K; Psaras T; Stützer H; Lackner K; Schicha H
Nucl Med Commun; 1999 Mar; 20(3):255-61. PubMed ID: 10093075
[TBL] [Abstract][Full Text] [Related]
11. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878
[TBL] [Abstract][Full Text] [Related]
12. [The usefulness of whole body FDG-PET/CT in patients with brain metastasis].
Nakagawa K; Aoyagi M; Inaji M; Maehara T; Toriyama H; Kawano Y; Tamaki M; Nariai T; Ohno K
No Shinkei Geka; 2009 Feb; 37(2):159-66. PubMed ID: 19227157
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
14. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
Kaya AO; Coskun U; Unlu M; Akdemir UO; Ozdemir NY; Zengin N; Benekli M; Yildiz R; Yaman E; Ozturk B; Gumus M; Uner A; Yamac D; Ucgul E; Buyukberber S
Asian Pac J Cancer Prev; 2008; 9(4):683-6. PubMed ID: 19256759
[TBL] [Abstract][Full Text] [Related]
15. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
16. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
17. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Manohar K; Bhattacharya A; Mittal BR
Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
[TBL] [Abstract][Full Text] [Related]
18. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine.
Pirotte B; Goldman S; David P; Wikler D; Damhaut P; Vandesteene A; Salmon L; Brotchi J; Levivier M
Acta Neurochir Suppl; 1997; 68():133-8. PubMed ID: 9233429
[TBL] [Abstract][Full Text] [Related]
20. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy.
Rohren EM; Provenzale JM; Barboriak DP; Coleman RE
Radiology; 2003 Jan; 226(1):181-7. PubMed ID: 12511688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
